Skip to main content
Clinical Trials/NL-OMON51372
NL-OMON51372
Recruiting
N/A

A biomarker assessment study to investigate the influence of high-frequency chest wall oscillations on the clearance of cerebrospinal fluid biomarkers - Cerebrospinal fluid biomarker clearance

Centre for Human Drug Research0 sites34 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Centre for Human Drug Research
Enrollment
34
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Signed informed consent prior to any study\-mandated procedure
  • 2\. Healthy male or female subjects, 18 to 50 years of age, inclusive at
  • 3\. Body mass index (BMI) between 18 and 30 kg/m2, inclusive at screening, and
  • with a minimum weight of 50 kg.
  • 4\. All women of childbearing potential must practice effective contraception
  • during the study.
  • 5\. Has the ability to communicate well with the Investigator in the Dutch
  • language and willing to comply with the study restrictions.

Exclusion Criteria

  • 1\. Evidence of any active or chronic disease or condition that could interfere
  • with, or for which the treatment of might interfere with, the conduct of the
  • study, or that would pose an unacceptable risk to the subject in the opinion of
  • the investigator (following a detailed medical history, physical examination,
  • vital signs (systolic and diastolic blood pressure, pulse rate, body
  • temperature) and 12\-lead electrocardiogram (ECG)). Minor deviations from the
  • normal range may be accepted, if judged by the Investigator to have no clinical
  • 2\. Clinically significant abnormalities, as judged by the investigator, in
  • laboratory test results (including hepatic and renal panels, complete blood
  • count, chemistry panel and urinalysis). In the case of uncertain or

Outcomes

Primary Outcomes

Not specified

Similar Trials